Protein Kinase Inhibitors: all 15,766 studies that test it

Page 29 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• A Target Occupancy Study With Ritlecitinib.CompletedNCT05128058Phase 1Results posted
• Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis InvolvementCompletedNCT05127421Phase 2Results posted
• PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT05119569Phase 2Results posted
• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2Results posted
• Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2Results posted
• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
• Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 AntihistamineCompletedNCT05107115Phase 2Results posted
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT05105841Phase 2Results posted
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)CompletedNCT05103358Phase 2Results posted
• Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerCompletedNCT05101564Phase 2Results posted
• Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of TolbutamideCompletedNCT05097716Phase 1Results posted
• A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05089019Phase 1Results posted
• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
• Dual JAK1/TYK2 Inhibitor for Cicatricial AlopeciaCompletedNCT05076006Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Children With COVID-19TerminatedNCT05074420Phase 3Results posted
• Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaTerminatedNCT05073458Phase 3Results posted
• Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsActive, not recruitingNCT05071209Phase 1/2Results posted
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsTerminatedNCT05071183Phase 1/2Results posted
• Phase II Trial of Vemurafenib and Sorafenib in Pancreatic CancerCompletedNCT05068752Phase 2Results posted
• Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Phase 2Results posted
• A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy ParticipantsCompletedNCT05067439Phase 1Results posted
• A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung FibrosisCompletedNCT05065190Phase 3Results posted
• Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesCompletedNCT05064488Phase 1Results posted
• A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)CompletedNCT05064332Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisCompletedNCT05061693Phase 2Results posted
• Study of Vimseltinib for Tenosynovial Giant Cell TumorActive, not recruitingNCT05059262Phase 3Results posted
• Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCCompletedNCT05057247Phase 2Results posted
• A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or IITerminatedNCT05055258Phase 2Results posted
• Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results posted
• A Study of GFH018 in Patients With Advanced Solid TumorsCompletedNCT05051241Phase 1Results posted
• A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistaminesCompletedNCT05048342Phase 3Results posted
• Evaluation of Tofacitinib in Prevention of Photosensitivity in LupusCompletedNCT05048238Phase 1Results posted
• European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataCompletedNCT05041803Phase 3Results posted
• A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy AdultsCompletedNCT05040295Phase 1Results posted
• Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown OriginCompletedNCT05038982Phase 2Results posted
• Preventing Anaphylaxis With AcalabrutinibCompletedNCT05038904Phase 2Results posted
• A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaTerminatedNCT05036681Phase 2Results posted
• Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib CapsuleCompletedNCT05032690Phase 1Results posted
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistaminesCompletedNCT05032157Phase 3Results posted
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 AntihistaminesCompletedNCT05030311Phase 3Results posted
• A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT05028751Phase 1/2Results posted
• A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT05023980Phase 3Results posted
• Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT05021900Phase 2Results posted
• Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AMLTerminatedNCT05020665Phase 3Results posted
• Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisCompletedNCT05018806Phase 2Results posted
• To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsCompletedNCT05014828Phase 2Results posted
• A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic DermatitisCompletedNCT05014438Phase 2Results posted
• Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
• NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)CompletedNCT05005845Phase 2Results posted
• Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsCompletedNCT05003622Phase 1Results posted
• Study of NDI-034858 in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04999839Phase 2Results posted
• Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic DermatitisCompletedNCT04992546Phase 2Results posted
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Phase 3Results posted
• Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedNCT04985604Phase 2Results posted
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
• Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsTerminatedNCT04972110Phase 1/2Results posted
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingNCT04971226Phase 3Results posted
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results posted
• Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 TrialsCompletedNCT04949841Phase 3Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Phase 3Results posted
• Asciminib Treatment Optimization in ≥ 3rd Line CML-CPCompletedNCT04948333Phase 3Results posted
• A Study of CC-99677 in Participants With Active Ankylosing SpondylitisTerminatedNCT04947579Phase 2Results posted
• Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerActive, not recruitingNCT04941287Phase 2Results posted
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerActive, not recruitingNCT04940052Phase 3Results posted
• A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg CapsuleCompletedNCT04938453Phase 1Results posted
• Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasTerminatedNCT04933617Phase 1Results posted
• Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT04930562Phase 2Results posted
• Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerActive, not recruitingNCT04929392Phase 2Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental VitiligoCompletedNCT04927975Phase 2Results posted
• Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCTerminatedNCT04926831Phase 2Results posted
• Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedNCT04925986Phase 2Results posted
• Novel Experimental COVID-19 Therapies Affecting Host ResponseCompletedNCT04924660Phase 2/3Results posted
• Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasActive, not recruitingNCT04924608Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)CompletedNCT04921969Phase 3Results posted
• Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction CaCompletedNCT04921904Phase 1/2Results posted
• Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Phase 3Results posted
• Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed ConditionCompletedNCT04916769Phase 1Results posted
• Study of Ruxolitinib Cream for the Treatment of Discoid Lupus ErythematosusCompletedNCT04908280Phase 2Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsActive, not recruitingNCT04908202Phase 3Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingNCT04908189Phase 3Results posted
• A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.CompletedNCT04903093Phase 1Results posted
• Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer PatientsCompletedNCT04902885Phase 3Results posted
• A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)CompletedNCT04896385Phase 2Results posted
• A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised PatientsCompletedNCT04890509Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results posted
• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2Results posted
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)CompletedNCT04882917Phase 1Results posted
• RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCompletedNCT04877990Phase 2Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)CompletedNCT04872101Phase 3Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand EczemaCompletedNCT04871711Phase 3Results posted
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyCompletedNCT04865289Phase 3Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)TerminatedNCT04863248Phase 2Results posted
• Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedNCT04862143Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Active, not recruitingNCT04857034Phase 2Results posted

← Protein Kinase Inhibitors overview